We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
Read MoreHide Full Article
Key Takeaways
FDA narrowed Elevidys' use to ambulatory DMD patients and added boxed warnings for severe liver risks.
SRPT must add limits for liver impairment, recent vaccinations or infections and expand monitoring needs.
SRPT will run an observational study and develop a revised regimen to address liver injury concerns.
Sarepta Therapeutics (SRPT - Free Report) announced that the FDA has approved significant changes to the label of Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The revised labeling not only narrows the eligible patient population but also adds new safety restrictions that further define how the therapy should be used.
Under the updated label, Elevidys is now approved only for ambulatory patients aged four years and older with DMD. It is no longer authorized for use in non-ambulatory patients. The gene therapy has been mandated to carry a boxed warning — the most important safety warning issued by the FDA — highlighting the risks of acute liver failure (ALF) and acute liver injury (ALI).
The agency also added additional limitations to Elevidys’ label. The gene therapy is no longer recommended for patients with pre-existing liver impairment, recent vaccinations or active/recent infections. The updated label also introduces new monitoring requirements, including weekly liver function tests for at least three months post-treatment. Patients are advised to remain near an appropriate medical facility for at least two months after infusion to ensure rapid access to care if complications arise.
These changes align with escalating safety concerns that have pressured Sarepta in recent months. Investor sentiment toward the stock has worsened significantly after two patient deaths were linked to Elevidys, both caused by ALF in non-ambulatory DMD patients. Before this label update, Sarepta had voluntarily suspended both clinical and commercial Elevidys dosing in this population.
As part of the postmarketing obligations, Sarepta is also required to conduct an observational study to further evaluate the risk of serious liver injury. The study will enroll roughly 200 DMD patients and follow them for at least 12 months after receiving Elevidys.
SRPT’s Stock Performance
Despite the substantial label changes, SRPT shares rose nearly 6% on Friday’s trading session. The positive move likely reflected relief among investors that Elevidys was not pulled from the market entirely, even with the added restrictions and boxed warning. The therapy remains Sarepta’s key commercial driver, and retaining market availability — even for a narrower patient population — appears to have eased some of the worst-case regulatory concerns.
Year to date, the stock has plummeted nearly 85% against the industry’s 15% growth.
Image Source: Zacks Investment Research
More on Sarepta’s Elevidys
To address the safety issues observed in non-ambulatory patients, Sarepta has disclosed that it is developing a revised treatment protocol featuring an enhanced, sirolimus-based immunosuppressive regimen. The goal is to reduce the risk of acute liver complications and improve the safety profile of Elevidys in this higher-risk subgroup. The company plans to initiate a clinical study of this updated regimen soon, to eventually resume dosing in the non-ambulatory population pending FDA review.
Sarepta developed Elevidys in partnership with pharma giant Roche (RHHBY - Free Report) . In 2019, the company and Roche entered into a licensing agreement to develop Elevidys. Per the agreement, Roche has exclusive rights to launch and market the therapy in non-U.S. markets.
EPS estimates for Alkermes’ 2025 have increased from $1.82 to $1.96, while those for 2026 have risen from $1.70 to $1.77 in the past 60 days. ALKS stock has gained 1% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average negative surprise of 4.58%.
In the past 60 days, estimates for CorMedix’s earnings per share (EPS) have increased from $1.52 to $2.90 for 2025. During the same time, EPS estimates for 2026 have increased from $2.09 to $2.72. Year to date, shares of CRMD have rallied 39%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.04%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
Key Takeaways
Sarepta Therapeutics (SRPT - Free Report) announced that the FDA has approved significant changes to the label of Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The revised labeling not only narrows the eligible patient population but also adds new safety restrictions that further define how the therapy should be used.
Under the updated label, Elevidys is now approved only for ambulatory patients aged four years and older with DMD. It is no longer authorized for use in non-ambulatory patients. The gene therapy has been mandated to carry a boxed warning — the most important safety warning issued by the FDA — highlighting the risks of acute liver failure (ALF) and acute liver injury (ALI).
The agency also added additional limitations to Elevidys’ label. The gene therapy is no longer recommended for patients with pre-existing liver impairment, recent vaccinations or active/recent infections. The updated label also introduces new monitoring requirements, including weekly liver function tests for at least three months post-treatment. Patients are advised to remain near an appropriate medical facility for at least two months after infusion to ensure rapid access to care if complications arise.
These changes align with escalating safety concerns that have pressured Sarepta in recent months. Investor sentiment toward the stock has worsened significantly after two patient deaths were linked to Elevidys, both caused by ALF in non-ambulatory DMD patients. Before this label update, Sarepta had voluntarily suspended both clinical and commercial Elevidys dosing in this population.
As part of the postmarketing obligations, Sarepta is also required to conduct an observational study to further evaluate the risk of serious liver injury. The study will enroll roughly 200 DMD patients and follow them for at least 12 months after receiving Elevidys.
SRPT’s Stock Performance
Despite the substantial label changes, SRPT shares rose nearly 6% on Friday’s trading session. The positive move likely reflected relief among investors that Elevidys was not pulled from the market entirely, even with the added restrictions and boxed warning. The therapy remains Sarepta’s key commercial driver, and retaining market availability — even for a narrower patient population — appears to have eased some of the worst-case regulatory concerns.
Year to date, the stock has plummeted nearly 85% against the industry’s 15% growth.
Image Source: Zacks Investment Research
More on Sarepta’s Elevidys
To address the safety issues observed in non-ambulatory patients, Sarepta has disclosed that it is developing a revised treatment protocol featuring an enhanced, sirolimus-based immunosuppressive regimen. The goal is to reduce the risk of acute liver complications and improve the safety profile of Elevidys in this higher-risk subgroup. The company plans to initiate a clinical study of this updated regimen soon, to eventually resume dosing in the non-ambulatory population pending FDA review.
Sarepta developed Elevidys in partnership with pharma giant Roche (RHHBY - Free Report) . In 2019, the company and Roche entered into a licensing agreement to develop Elevidys. Per the agreement, Roche has exclusive rights to launch and market the therapy in non-U.S. markets.
SRPT’s Zacks Rank
Sarepta currently carries a Zacks Rank #3 (Hold).
Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Alkermes (ALKS - Free Report) and CorMedix (CRMD - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
EPS estimates for Alkermes’ 2025 have increased from $1.82 to $1.96, while those for 2026 have risen from $1.70 to $1.77 in the past 60 days. ALKS stock has gained 1% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average negative surprise of 4.58%.
In the past 60 days, estimates for CorMedix’s earnings per share (EPS) have increased from $1.52 to $2.90 for 2025. During the same time, EPS estimates for 2026 have increased from $2.09 to $2.72. Year to date, shares of CRMD have rallied 39%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.04%.